Sign In
Buy IKT
$1.70
-0.0100 (-0.585%)
At Close: Jun 02, 2026
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
08:05am, Wednesday, 03'rd Apr 2024
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonar
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
05:13pm, Thursday, 28'th Mar 2024
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
04:15pm, Wednesday, 27'th Mar 2024
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinas
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
04:05pm, Wednesday, 28'th Feb 2024
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate Company to pursue eleven indications for IkT-001Pro; all previously approved for treat
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
10:56am, Thursday, 15'th Feb 2024
Inhibikase Therapeutics, Inc. (IKT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong a
New Strong Buy Stocks for February 13th
07:51am, Tuesday, 13'th Feb 2024
IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.
Best Momentum Stocks to Buy for February 8th
11:01am, Thursday, 08'th Feb 2024
POST, IKT and ACMR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 8, 2023.
New Strong Buy Stocks for February 8th
07:41am, Thursday, 08'th Feb 2024
IKT, POST, ASAN, ACMR and HENKY have been added to the Zacks Rank #1 (Strong Buy) List on February 8, 2023.
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson's disease - - The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Park
New Strong Buy Stocks for February 6th
10:01am, Tuesday, 06'th Feb 2024
EGO, SBSI, CCS, TCBX and IKT have been added to the Zacks Rank #1 (Strong Buy) List on February 6, 2023.
Best Momentum Stocks to Buy for January 31st
11:01am, Wednesday, 31'st Jan 2024
ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.
New Strong Buy Stocks for January 31st
07:05am, Wednesday, 31'st Jan 2024
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
09:05am, Monday, 29'th Jan 2024
BOSTON and ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase
Best Momentum Stocks to Buy for January 26th
11:01am, Friday, 26'th Jan 2024
PCAR, IKT and PD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 26, 2023.
